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Available online 15 June 2016Medical therapies in oncology have resulted in better survival resulting in a large population who are at risk of
early and late cardiac complications of chemotherapy. Cardiotoxicity related to chemotherapy can manifest de-
cades after treatment with a threefold higher mortality rate as compared to idiopathic dilated cardiomyopathy.
The leading cause of death in cancer survivors seems to be cardiac. Early detection and intervention could prevent
progression of heart failure to end stage disease requiring advanced therapies such as implantation of ventricular
assist devices or cardiac transplantation. This review focuses on the role of exercise in cardioprotection in this
population. The current practice of depending on ejection fraction for diagnosis of heart failure is suboptimal
to detect subclinical disease. It is also important to diagnose and treat early diastolic dysfunction as this tends
to lead to heart failure with preserved ejection fraction. Hence we suggest an algorithm here that is based on
using strain rate and tissue Doppler imaging modalities to detect subclinical systolic and diastolic dysfunction.
Further research is warranted in terms of deﬁning exercise prescriptions in this population. Human studies
with multicenter participation in randomized controlled trials should be done to elucidate the intricacies of
aerobic exercise intervention in cardiotoxicity dependent heart failure. It is also necessary to assess the utility
of exercise interventions in the different chemotherapeutic regimens as they impact the outcomes.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The impressive development of medical therapies in oncology has
resulted in better survival and consequently in a large population of sur-
vivors who are at risk of early and late cardiac complications secondary. This is an open access article underto chemotherapy. Chemotherapy-related cardiomyopathy (CRC) can
manifest decades after treatment with a threefold higher mortality
rate as compared to idiopathic dilated cardiomyopathy [1]. The 5-year
survival rate for all cancers in the US has increased from 50% in
1975–1977 to 68% in 1999–2005. The leading cause of death in cancer
survivors seems to be cardiac [1–4]. This review focuses on the possible
role of exercise in preventing onset and progression of heart failure in
CRC patients and attempts to highlight the need for more detailedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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treated with different chemotherapeutic agents.
1.1. Chemotherapy-related cardiotoxicity versus cardiac hypersensitivity
Cardiotoxicity can be deﬁned as a direct effect of chemotherapy
resulting in cardiac dysfunction which may lead to reversible/irrevers-
ible heart failure. From a retrospective review of trastuzumab clinical
trials CRC has been deﬁned as one or more of the following;
a) reduction of LVEF (global or speciﬁc to the interventricular septum);
b) symptoms or signs of heart failure (HF); c) decrease in LVEF from
baseline ≤5% to b55% in the presence of signs or symptoms of HF, or a
reduction in LVEF ≥10% to b55% without signs or symptoms of HF [5]
Cardiotoxicity related cardiac dysfunction (CRCD) is divided into 2
types. Type I consists of cardiac disease secondary to anthracycline.
Increased production of oxygen free radicals and oxidative stress with
abnormalities in mitochondrial metabolism as well as lysosomal
structure and function has been attributed to be the etiology of
cardiotoxicity [6]. Anthracyclines are also noted to impair iron metabo-
lism and therefore cause iron accumulation in the cardiac myocytes [7].
Many factors including cumulative dosage of anthracycline as well as
concomitant use of other drugs, age and female gender have been impli-
cated in the toxicity noted [8,9]. Type II is induced by trastuzumab.
Trastuzumab is a monoclonal, humanized antibody. It is FDA approved
for treatment of HER2 positive breast cancers. Cardiotoxicity secondary
to trastuzumab has been noted to be reversible status post-discontinu-
ation of the drug and well-tolerated on repeat dosing. Patients show
reduced ejection fraction but are asymptomatic with no overt heart fail-
ure [10–12]. However when dosed with anthracyclines it is known to
worsen the cardiotoxicity.
Cardiac hypersensitivity reactions should be distinguished from
cardiotoxicity produced by chemotherapeutic agents. The cardiovascu-
lar system acts both as a source aswell as a target for mediators of aller-
gic reactions. Mast cells reside largely around the adventitia of large
coronary arteries in close apposition with the small intramural vessels.
Cardiac mast cells respond to IgE-mediated stimuli [13,14], and can
also be activated by other stimuli such as anaphylatoxins (C3a and
C5a), substance P and eosinophilic cationic proteins [14]. With increase
in use of chemotherapeutic agents there is a concomitant increase in
incidence of hypersensitivity reactions. Premedication, skin testing,
and desensitization protocols may be useful in abating these reactions
especially in patients with a history of hypersensitivity [15,16].
1.2. Role of cardiovascular imaging in deﬁning cardiotoxicity
A number of chemotherapeutic agents have been linked to heart
failure with reduced ejection fraction (HFrEF) with one of the topmost
offenders being the anthracyclines [17]. Left ventricular ejection fraction
(LVEF) is usually assessed at baseline and following every cycle but no
deﬁnite universal guidelines exist for the frequency of these examina-
tions in different chemotherapeutic regimens. In the 2012 guidelines
by the European Society of Medical Oncology (ESMO) the frequency of
echocardiographic surveillance has been discussed essentially for
patients undergoing treatment with anthracycline regimens [18]. Dif-
ferentmodalities ranging from2Dechocardiography to cardiacmagnet-
ic resonance are used in different institutions to assess left ventricular
functionmaking it highly non-uniformand variable. Stress echocardiog-
raphy may detect cardiomyopathy at the subclinical level, so that early
treatment could be initiated before heart failure progresses to an
irreversible stage [19]. Strain rate imaging is a newmodality using echo-
cardiographic techniques to assess early subclinical disease [20–22].
Tissue Doppler imaging is the most widely used technique for
assessing diastolic dysfunction currently. Cardiac troponin I (cTnI) and
brain natriuretic peptide (BNP) are also used for risk stratiﬁcation and
prognostication [23–24]. Early identiﬁcation of patientswhoare suscep-
tible to cardiotoxicity may prevent morbidity and mortality [25–27].Table 1 lists selected studies using different cardiovascular imaging
techniques for predicting clinical outcomes in patients experiencing
cancer therapy related cardiotoxicity [2,28–43]. Mutigated acquisition
(MUGA), 2D and 3D echocardiography have been shown to be useful
to varying degrees. Cardiac magnetic resonance (CMRI) still remains
the gold standard. CMRI is limited due to the high cost of installation
and operation as well as technical difﬁculties in patients with metallic
prosthesis and devices. The pros and cons of each of the techniques
are listed in Table 1. Noninvasive imaging continues to be used for
assessing LVEF for risk stratiﬁcation, diagnosis and prognosis. Many
more investigations will be needed in the area of noninvasive imaging
techniques for risk stratiﬁcation and prognostication in this population.
Three-dimensional echocardiography-derived LVEF appears to be
reliable in patients receiving chemotherapy [43]. Global longitudinal
strain (GLS) and strain rate detect subclinical changes during chemo-
therapy, radiation and trastuzumab treatment before changes in LVEF
are detectable [44]. In an athletic healthy population, cardiac strain
changes are noted in response to exercise training [45]. GLS has been
used in the oncology population to predict early subclinical changes
[21]. GLS has been shown to be predictive of all-cause mortality in the
heart failure population [46–49] but this remains to be demonstrated
in cancer survivors.
Endothelial function and cardiac biomarkers can be used to predict
and identify cardiotoxicity [50–52]. However both endothelial function
and biomarkers need further testing and validation in the cancer
population.
2. Clinical studies assessing beneﬁts of exercise
Early detection and intervention may prevent progression of
heart failure to Stage D requiring surgical therapies such as
placement of a ventricular assist device or cardiac transplantation.How-
ever high level evidence is still lacking in clinical decision making
regarding early detection and management of chemotherapy related
cardiotoxicity [43]. Identiﬁcation of subclinical disease prior to appear-
ance of symptoms would be the key factor to prevent cardiovascular
injury and enhance survival as well as quality of life. Additionally such
a strategy would also help in initiating standard heart failure therapies
ahead of time before the patient becomes symptomatic.
Studies including randomized clinical trials appear to be conducted
in small groups of patients undergoing treatment for cancer notably of
the breast. The highlights of these exercise studies point to increased
VO2 max, decreased heart rate and decreases in systolic and diastolic
blood pressure [53–58]. Interestingly, exercise therapy does not seem
to prevent ventricular remodeling secondary to trastuzumab when
used as adjuvant therapy [59] suggesting that combinations of chemo-
therapeutic agents may affect multiple molecular targets all of which
may not be modulated by exercise. In a study of 123 women assigned
to supervised, self-directed or standard care the best beneﬁt in patients
who underwent chemotherapy was in the self-directed exercise group.
Supervised exercise was of beneﬁt only in cancer patients not receiving
any chemotherapy. No signiﬁcant differences were noted between the
groups in their quality of life assessment [60]. In a home-based walking
study in stages 1–3 breast cancer patients who were starting ﬁrst line
adjuvant therapy signiﬁcant beneﬁts were observed. The exercise
regimenwas home-based and consisted of aerobic exercise andwalking
for 30 min 3 times a week. The patients appeared to beneﬁt in terms of
signiﬁcant increase in VO2max aswell as 6minwalk test [61]. The stud-
ies on patients in the post-treatment period also seem to beneﬁt from
supervised as well as home based exercise regimen [62–65]. In a study
of 113 women role of exercise during and after treatment was assessed.
It was interesting that the group that had maximal beneﬁt consisted of
the women who underwent a prescriptive exercise program. These
individuals showed improvement in the cardiopulmonary parameters
as well as their fatigue levels suggesting that exercise intervention
earlier could be beneﬁcial [66]. Table 2 lists some of the recent
Table 1
Comparison of cardiovascular imaging techniques in deﬁning cardiotoxicity.
Imaging Parameter of cardiotoxicity Pros Cons References
MUGA LVEF Reproducible calculation Gives no information on DD [28]
Low operator variability Involves radiation use
Serial testing is possible Cannot detect subclinical disease
Comparable to CMR which is the gold standard
2DE LVEF Assesses systolic and diastolic function High operator variability [29,30]
Tissue Doppler techniques assess diastolic function Preload dependence
Non-invasive Cannot detect subclinical disease
No radiation involved
Serial testing is possible
RT3DE LVEF Assesses systolic and diastolic function [29,30,43]
Low operator variability Preload dependence
Serial testing is possible Cannot detect subclinical disease
More powerful than 2DE
Comparable to CMR which is the gold standard
SRI GLS, LS Detects subclinical disease and useful in prognostication Vendor variability [2,31–36,44]
Used in combination with 2DE
CCT Coronary calcium,
LVEF, atherosclerosis
Assesses coronary atherosclerosis No deﬁnite studies [37]
Contrast nephropathy
MRI LVEF, high resolution of
structure and function
Non-invasive High cost [38–42]
No radiation involved Unavailable in all hospitals
Serial testing is possible Requirement of advanced technology
Best correlation of structure and function and skilled personnel
Gold standard for LVEF determination Contraindicated with metal implants
Characterization of myocardial tissue Gadolinium induced retroperitoneal ﬁbrosis
With renal insufﬁciency
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heart failure secondary to cardiotoxicity.
3. Possible cellular and molecular basis of exercise induced changes
in CRC
Anthracyclines in general cause severe cardiotoxicity via upregula-
tion of the reactive oxygen species. It has been thought that this can
happen as a two-pronged process because of the semi-quinone group
generated via interactionswith endothelial nitric oxide synthase induc-
ing excessive free radical production [67]. Additionally it disrupts
topoisomerase 2B activity which in turn can cause breaks in double-
stranded DNA leading to activation of p53 tumor suppressor gene,
increased reactive oxygen species (ROS) production, increased
mitochondrial dysfunction and consequent cell dysfunction and death.
ROS produced can independently increase protein, nucleic acid, lipid
peroxidation increasing apoptosis and cell death. These effects are
attenuated by aerobic exercise. Exercise causes upregulation of antioxi-
dant and anti-apoptotic capacity.Table 2
Effect of exercise in chemotherapy patients.
Author Study type
Type of chemotherapeutic
agent
Subjects
(n) Typ
Corneya et al. [53,54] Randomized
Trial (RT)
Herceptin/taxane 242,301 Sta
com
exe
Corneya et al. [54] RT subgroup
analysis
Herceptin/taxane 301 Sta
com
exe
Corneya et al. [55]
(START)
RT Adjuvant chemotherapy 242 Usu
res
Corneya et al. [54,63] RT Herceptin/taxane 301,58
Hornsby et al. [56] RT Doxorubicin/cyclophosphamide 20 Ae
Haykowsky et al. [59] Observational Trastuzumab adjuvant therapy 17 Ae
tre
Vincent et al. [61] Observational First line adjuvant therapy per
protocol
39 Ho
⁎ Standard dose = 25 to 30 minutes of aerobic exercise three times a week
⁎⁎ Higher volume = 50 to 60 minutes of aerobic exercise three times a weekAt the molecular level the cardiac muscle is said to be protected by
activation of pathways that use gp130 cytokines and neuregulin.
Neuregulin-1 (NRG-1) is a paracrine factor produced by endothelial
cells of the microvasculature and is upregulated in heart failure.
Circulating levels of NRG-1β were assayed in heart failure patients and
found to have signiﬁcant prognostic value.
It was found to be independently associated with increased risk of
mortality or need for cardiac transplantation and demonstrated signiﬁ-
cant correlations with NYHA class and disease severity. [68]. In another
small study of chronic HF patients HER2 upregulated in chronic heart
failure correlated signiﬁcantly with New York Heart Association class
[69]. The decreased NRG1/ErbB signaling and increases in angiotensin
II and adrenergic agonists were combated by exercise by increasing
mechanical stress and depression of the neurohormonal system. Addi-
tionally exercise appears to cause increases in myocardial AKT thereby
decreasing pathological LV remodeling and hypertrophy [70–73].
When trastuzumab is dosed with anthracycline, it inhibits the ErbB2
receptor, resulting in loss of the neuregulin-dependent pathways
and consequent death of cardiac myocytes. Another importante of exercise regimen Conclusions
ndard*, higher volume** and
bination of resistance and aerobic
rcise
Possible positive outcome in the higher
volume group
ndard*, higher volume** and
bination of resistance and aerobic
rcise
Women may beneﬁt from the higher volume
exercise regimen
al care, supervised aerobic and
istance training during chemotherapy
Exercise may improve outcomes
(no statistical signiﬁcance)
Higher volume exercise regimen or
combined may be better than standard,
better quality of life
robic training Aerobic training improved the VO2 max
robic exercise before and after
atment
No effect of aerobic exercise in left
ventricular remodeling
me based walking therapy Signiﬁcant improvement of VO2 max
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AKT [74].
Exercise increases myocardial AKT and possibly counteracts the
pathological effects. Cancer therapies that target vascular endothelial
growth factor (VEGF) as well as the use of other molecularly targeted
therapies such as tyrosine kinase inhibitors cause anti-angiogenesis
which in turn affects cardiac function. Tyrosine kinase inhibitors affect
a variety of enzymes resulting in mitochondrial dysfunction [75]. It
has been hypothesized that exercise results in upregulation of VEGF
and endothelial progenitor cells (EPCs) by activation of stat 3 which in
turn causes erythropoietin mediated differentiation of cardiac progeni-
tor cells into endothelial cells [73]. Fig. 1 shows a simpliﬁed view of the
complex molecular mechanisms possibly underlying cardiotoxicity and
the counteracting effects of exercise in this population.
4. Exercise prescription
Fig. 2 shows a suggested algorithm in cardiotoxicity induced by
chemotherapeutic agents. The current practice of depending on ejection
fraction for diagnosis of heart failure is suboptimal to detect subclinical
disease. It is also important to diagnose and treat early diastolic dysfunc-
tion as this tends to lead to heart failure with preserved ejection
fraction. This algorithm is based on utilizing strain rate and tissue Dopp-
ler imaging modalities to detect subclinical systolic and diastolic dys-
function and the use of exercise as tolerated.
5. Conclusions
Based on the existing literature it is imperative that further research
is warranted in terms of deﬁning exercise prescriptions in this popula-
tion. Human studies with multicenter participation in randomized
controlled trials should be done to elucidate the intricacies of aerobic
exercise intervention in cardiotoxicity dependent heart failure. In the
molecularly targeted therapies the use of aerobic exercise intervention
is still debated. It is possible that the existing studies are small and not
randomized and hence may not reﬂect the true beneﬁt. This is an area
that deﬁnitely calls for large randomized controlled trials to deﬁne exer-
cise prescription. In addition, a better understanding of molecular
mechanisms operating in aerobic exercise is needed. This will pave
the way for larger studies which have adequate power to investigate
the role of exercise in the patient populations in whom several different
combinations of chemotherapeutic agents are used. Therefore a multi-
disciplinary approach involving other relevant specialties includingFig. 1. Possible molecular mechanisms iexercise physiologists and physical medicine specialists would be bene-
ﬁcial in arriving at the right exercise prescriptions.
6. Future perspectives
Role of physical exercise for prevention of cardiovascular toxicity in
the clinical setting still requires rigorous investigations. Most investiga-
tions have been done in breast cancer in the context of doxorubicin.
Future investigations are warranted to assess exercise as a deﬁnite
method for the reduction of cardiovascular morbidity and mortality in
cancer survivors in general. Translation of preclinical experiments to
the human system requires deﬁnition of sensitive diagnostic and out-
come measures as well as an optimal exercise prescription.
The deﬁnition of an exercise prescription remains ambiguous.
Though, moderate intensity exercise 3 times weekly was found to
improve systolic function in heart failure patients [72], derivation of
an optimal exercise prescription in the chemotherapy population
needs further investigations as it is currently more challenging to
balance exercise tolerance with deﬁned improvements in protection
of cardiac function. Existing studies use high intensity aerobic exercise
regimens in animal models treated with chemotherapeutic agents as
well as in the non-cancer heart failure populations [76,77] Such regi-
mens may not be tolerated in patients undergoing cancer chemothera-
py because of fatigue and deconditioning.
Use of exercise in the current literature is driven by improvements and
functionality. Existing studies essentially focus on doxorubicin toxicity
[78] hence it is imperative that future studies are needed to investigate
toxicities of other drugs and combinations of chemotherapeutic agents.
The dosage of these agents and duration of therapy also need to be inves-
tigated in the context of low, moderate and high intensity exercise
regimens. Studies are lacking at this time alsowith respect to relevant im-
provements in cardiac function at the molecular and biochemical levels.
In animal model systems several studies exist to support exercise
prevention [79–86]. Future clinical investigations in patients are needed
to prescribe appropriate intensity, frequency, duration, and timing of
exercise for primary and secondary prevention of cardiotoxicity
resulting from the several different chemotherapeutic regimens that
are currently available.
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